Scandinavian Prostate Cancer Group
Scientific research group
The Scandinavian Prostate Cancer Group (SPCG) is a group of scientific researchers who have conducted a series of clinical trials of treatments for prostate cancer. The group was founded in 1981 and the first study, SPCG-1, began in 1984.
Clinical trials
The studies conducted by the SPCG include the following:
SPCG-1 – estramustine phosphate versus diethylstilbestrol for high-risk advanced prostate cancer
SPCG-2 – orchiectomy plus cyproterone acetate versus placebo for metastatic prostate cancer
SPCG-3 – cancelled
SPCG-4 – radical prostatectomy versus watchful waiting for localized prostate cancer
SPCG-5 – polyestradiol phosphate versus triptorelin or orchiectomy plus flutamide for advanced prostate cancer
SPCG-6 – bicalutamide monotherapy versus standard care (watchful waiting) for localized prostate cancer
SPCG-7 – endocrine therapy with versus without radiotherapy for locally advanced or aggressive localized prostate cancer
SPCG-8 – cancelled
SPCG-9 – cancelled
SPCG-10 – cancelled
SPCG-11 (Zometa European Study [ZEUS]) – zoledronic acid with standard prostate cancer therapy versus standard prostate cancer therapy alone for prevention of bone metastases in high-risk localized prostate cancer
SPCG-12 – docetaxel versus surveillance after radical prostatectomy without androgen deprivation therapy for high-risk localized prostate cancer
SPCG-13 – docetaxel versus surveillance after radical prostatectomy with androgen deprivation therapy for high-risk localized prostate cancer
SPCG-14 – docetaxel versus bicalutamide for prostate-specific antigen recurrence after radical prostatectomy or radiotherapy for localized prostate cancer
SPCG-15 – radical prostatectomy versus radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer
The SPCG-6 study was also known as Trial 25 of the Early Prostate Cancer (EPC) clinical trial programme.
Other work
The SPCG also published a 1997 literature review on combined androgen blockade for advanced prostate cancer.
This brief starts where responsible research should: with the source description of “Scandinavian Prostate Cancer Group” as scientific research group. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the science & nature register because the source frames it as scientific research group. Its deeper value depends on whether names, dates, institutions and citations support that framing.
Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated May 11, 2026. The linked authority identifier is Q111953927. The first chronological checks are 1981, 1984 and 1997.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Scandinavian Prostate Cancer Group”, its source revision and the description used here.
- Expand the search: follow Scandinavian Prostate Cancer Group primary sources, Scandinavian Prostate Cancer Group archive and Scandinavian research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Scandinavian Prostate Cancer Group”?
- Is the terminology current, historical or disputed?
- Which observation, specimen, dataset or publication supports the account?
Search terms from this dossier
This entry incorporates text from “Scandinavian Prostate Cancer Group” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.